Blocking one protein turns your immune cells into cancer-killing machines

The immune system already knows how to fight cancer. The problem has always been that it runs out of fuel too quickly. A team of researchers from Hebrew University of Jerusalem, Philipps University of Marburg, and MD Anderson Cancer Center may have found the switch that keeps it running.

By blocking a protein called Ant2, they changed how T cells — the immune system’s frontline fighters — produce and use energy. The result is cells that are more active, more durable, and more effective at destroying tumors. The finding was published in Nature Communications and highlighted again this week as the research gains international attention.

The key insight was counterintuitive. Ant2 sits inside the mitochondria, the structure that powers every cell in the body. When the protein is disabled, T cells can no longer generate energy the way they normally do. Instead of shutting down, they rewire. They adopt what researchers describe as a preactivated, “warmed-up” state — primed to fight before they even encounter a tumor.

That rewired state changes everything about how the cells perform. The modified T cells showed improved endurance, multiplied more quickly, and targeted cancer cells with greater precision. In mouse models with skin tumors, animals treated with Ant2-deficient T cells showed measurably smaller tumors compared to standard therapy.

What separates this discovery from many previous immunotherapy advances is that it doesn’t require permanent genetic modification. Small molecules that inhibit Ant2 produced the same activated state as genetic deletion — no permanent DNA alteration needed. That matters because drugs can be dosed, adjusted, and reversed in ways that gene edits cannot. It also means the approach could be combined with existing treatments: a patient’s T cells could be taken out, briefly conditioned with an Ant2 inhibitor, and reinfused ready to fight.

The metabolic logic is elegant. T cells fighting cancer operate in an energy-hostile environment — tumors actively deplete the nutrients immune cells need to stay active. By entering the body with a preconditioned metabolic program, the modified T cells stand a better chance of sustaining activity over time — precisely the condition where conventional immunotherapy tends to fail.

The research is preclinical and human trials have not yet been announced. Clinical experts estimate the timeline to human applications at approximately five to ten years, pending safety and dosing studies. The team’s next steps will focus on identifying which Ant2-inhibiting compounds are safest for systemic use, and on testing the approach in combination with existing cancer therapies including CAR-T cell protocols currently entering trials.